This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ota, T. Articles by Okada, M. Search for Related Content PubMed PubMed Citation Articles by Ota, T. Articles by Okada, M. Social Bookmarking                   What's this?

Reduction of Left Ventricular Hypertrophy with St. Jude Medical 19 mm Valve Prosthesis

Department of Surgery, Division , Kobe University School of Medicine, Kobe, Japan

Kazuhiko Iwahashi

Department of Surgery, Division , Kobe University School of Medicine, Kobe, Japan

Hitoshi Matsuda

Department of Surgery, Division , Kobe University School of Medicine, Kobe, Japan

Takuro Tsukube

Department of Surgery, Division , Kobe University School of Medicine, Kobe, Japan

Keiji Ataka

Department of Surgery, Division , Kobe University School of Medicine, Kobe, Japan

Masayoshi Okada

Department of Surgery, Division , Kobe University School of Medicine, Kobe, Japan

To determine the permissible range of the St. Jude Medical 19 mm valve (SJM19) as an aortic prosthesis, transvalvular maximal pressure gradient (maxPG) and postoperative reduction of left ventricular (LV) hypertrophy were examined in 21 patients (body surface area [BSA] 1.28-1.56 m2, mean 1.42 m²). Doppler echocardiographically measured maxPG at rest was 31 ±16 mmHg, which showed no significant difference from the differences in patients' diseases (aortic regurgitation=AR or stenosis=AS), or BSA. The maxPG, also measured during dobutamine administration when they were less than 40 mmHg at rest, increased significantly from 21 ± 11 mmHg to 32.1 ± 15 mmHg, having no differences from the differences in diseases or BSA. Reduction of LV hypertrophy was achieved postoperatively (mean postoperative period of ten months), with the reduction rates of 26 ± 19% in LV mass and 21 ± 15% in LV cross-sectional area. No significant differences were found between the reduction rates and the differences in the patients' diseases or BSA. These results indicate that, following the implantation of SJM19, LV hypertrophy was reduced in patients with AR as well as with AS, when their BSA values were less than 1.6 m2. However, limited use is recommended because the increase in pressure gradient during exercise cannot be ignored.

Angiology, Vol. 46, No. 11, 981-987 (1995)
DOI: 10.1177/000331979504601102


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?